Travere Therapeutics shares are trading lower after the company announced confirmatory data from the Phase 3 PROTECT study of FILSPARI.
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics has announced confirmatory data from the Phase 3 PROTECT study of FILSPARI, causing its shares to trade lower.
September 21, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Travere Therapeutics' stock is trading lower following the announcement of confirmatory data from the Phase 3 PROTECT study of FILSPARI.
The announcement of confirmatory data from the Phase 3 PROTECT study of FILSPARI has led to a decrease in the trading price of Travere Therapeutics' shares. This suggests that the market may have had higher expectations for the study results, leading to a negative impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100